2021
Soluble Biomarkers for Prediction of Vascular and Gastrointestinal Disease Severity in Patients with Systemic Sclerosis
Carnaru M, Hinchcliff M. Soluble Biomarkers for Prediction of Vascular and Gastrointestinal Disease Severity in Patients with Systemic Sclerosis. Current Treatment Options In Rheumatology 2021, 7: 21-38. DOI: 10.1007/s40674-021-00171-4.Peer-Reviewed Original ResearchSystemic sclerosisSeverity biomarkersHigh-sensitivity cardiac troponin TSensitivity cardiac troponin TInternal organ involvementPlasma growth factorsNoninvasive screening toolCardiac troponin TDisease biomarkersGI involvementNT-proBNPPulmonary hypertensionCardiac involvementOrgan involvementSerum autoantibodiesEndostatin levelsEndothelial microparticlesHigh morbiditySoluble biomarkersTreatment decisionsCell adhesion moleculeNew biomarkersDisease severityTroponin TDiagnostic testing
2018
The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts
Dougherty DH, Kwakkenbos L, Carrier ME, Salazar G, Assassi S, Baron M, Bartlett SJ, Furst DE, Gottesman K, van den Hoogen F, Malcarne VL, Mouthon L, Nielson WR, Poiraudeau S, Sauvé M, Boire G, Bruns A, Chung L, Denton C, Dunne JV, Fortin P, Frech T, Gill A, Gordon J, Herrick AL, Hinchcliff M, Hudson M, Johnson SR, Jones N, Kafaja S, Larché M, Manning J, Pope J, Spiera R, Steen V, Sutton E, Thorne C, Wilcox P, Thombs BD, Mayes MD, Albert A, Arsenault G, Bissonette L, Boutron I, Carreira P, Maia A, Dagenais P, Domsic R, El-Baalbaki G, Ells C, van den Ende C, Fligelstone K, Fortune C, Godard D, Gyger G, Harel D, Ikic A, Impens A, Jang Y, Artur Jose de B, Kennedy A, Khalidi N, Korman B, Leite C, Liang P, Marra C, Masetto A, Nielsen K, Portales A, Riggs R, Reyna T, Roux S, Schouffoer A, Steele R, Suarez-Almazor M, Varga J, Welling J, Wigley F, Wong-Rieger D, Cumin J, Delisle V, Fedoruk C, Fox R, Gholizadeh S, Jewett L, Levis B, Mills S, Pepin M, Persmann J, Turner K. The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. Rheumatology 2018, 57: 1623-1631. PMID: 29868924, DOI: 10.1093/rheumatology/key139.Peer-Reviewed Original ResearchConceptsIntervention Network CohortSPIN CohortSSc cohortAntibody frequencyCanadian Scleroderma Research Group cohortBaseline clinical featuresEuropean Scleroderma TrialsLarge SSc cohortPatient-reported outcome dataSSc renal crisisInterstitial lung diseasePatient-reported outcomesWeb-based cohortRenal crisisScleroderma cohortDcSSc patientsScleroderma TrialsOrgan involvementWhite patientsClinical featuresHigher proportionLung diseaseScleroderma patientsHigh prevalenceOutcome data
2017
A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis
Taroni JN, Greene CS, Martyanov V, Wood TA, Christmann RB, Farber HW, Lafyatis RA, Denton CP, Hinchcliff ME, Pioli PA, Mahoney JM, Whitfield ML. A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis. Genome Medicine 2017, 9: 27. PMID: 28330499, PMCID: PMC5363043, DOI: 10.1186/s13073-017-0417-1.Peer-Reviewed Original ResearchConceptsDisease-associated signaturesFunctional genomic networksGene expression signaturesPulmonary fibrosisAutoimmune diseasesDisease processMulti-organ autoimmune diseaseDistinct underlying pathologyPro-fibrotic macrophagesInternal organ involvementPulmonary arterial hypertensionExpression signaturesSkin of patientsInnate immune systemWilcoxon rank sum testGenomic networksRank sum testBackgroundSystemic sclerosisArterial hypertensionOrgan involvementSystemic sclerosisUnderlying pathologyLung microenvironmentSkin fibrosisFibrotic genes
2016
Molecular Stratification by Gene Expression as a Paradigm for Precision Medicine in Systemic Sclerosis
Hinchcliff M, Whitfield M. Molecular Stratification by Gene Expression as a Paradigm for Precision Medicine in Systemic Sclerosis. 2016, 657-670. DOI: 10.1007/978-3-319-31407-5_49.Peer-Reviewed Original ResearchSystemic sclerosisPatient subsetsProgressive interstitial lung diseaseDiffuse cutaneous systemic sclerosisAppropriate patient subsetsScleroderma renal crisisCutaneous systemic sclerosisInvestigator-initiated trialPulmonary arterial hypertensionSubset of patientsDifferent patient subsetsInterstitial lung diseaseDifferent pathophysiological processesMolecular pathwaysPrecision medicineGene expression subsetsT lymphocyte activationUninvolved skin samplesInflammatory subsetRenal crisisSSc complicationsArterial hypertensionMycophenolate mofetilClinical improvementOrgan involvement
2008
Systemic sclerosis/scleroderma: a treatable multisystem disease.
Hinchcliff M, Varga J. Systemic sclerosis/scleroderma: a treatable multisystem disease. American Family Physician 2008, 78: 961-8. PMID: 18953973.Peer-Reviewed Original ResearchConceptsInternal organ involvementSystemic sclerosisOrgan involvementRaynaud's phenomenonEndothelin-1 receptor blockerChronic connective tissue diseaseEnd-organ dysfunctionEnzyme inhibitor therapyHigh-dose corticosteroidsScleroderma renal crisisPulmonary arterial hypertensionPulmonary function testingConnective tissue diseaseDisease-modifying therapiesDistinct clinical subsetInternal organ dysfunctionOrgan-specific manifestationsPhosphodiesterase-5 inhibitorsMiddle-age womenOptimal patient careWidespread microvascular damageRenal crisisArterial hypertensionDigital ulcersLifestyle modification